Business Context and Reporting Period
Company: ORAMED PHARMACEUTICALS INC.
Filing Type: Form 8-K (Current Report)
Date of Report: January 22, 2013
Reporting Period: Single event date (January 22, 2013)
This filing reports a corporate action regarding the company's capital structure and trading status. The registrant is incorporated in Delaware with principal executive offices in Jerusalem, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
- Reverse Stock Split: On January 22, 2013, the company announced the effectiveness of a reverse stock split.
- Trading Symbol: The company announced a new trading symbol effective as of the report date.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the announcement of the reverse stock split. The document incorporates a press release (Exhibit 99.1) by reference for further details on the event.
Investor Verification Checklist
- Verify the specific ratio of the reverse stock split (not detailed in the 8-K text).
- Confirm the new trading symbol assigned to the company.
- Review the attached press release (Exhibit 99.1) for details on the rationale and impact of the stock split.
- Check subsequent filings for updated share count and financial position post-split.